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Summary
The term frontotemporal lobar degeneration (FTLD) de-
scribes a spectrum of neurodegenerative disorders asso-
ciated with deposition of misfolded proteins in the frontal
and temporal lobes. Up to 40% of FTLD patients reports
a family history of neurodegeneration, and approximately
1/3 of familial cases shows an autosomal dominant pat-
tern of inheritance of the phenotype. Over the past two
decades, several causative and susceptibility genes for
FTLD have been discovered, supporting the notion that
genetic factors are important contributors to the disease
processes. Genetic variants in three genes, MAPT, GRN
and C9orf72, account for about half of familial FTLD cas-
es. In addition, rare defects in the CHMP2B, VCP,
TARDBP, SQSTM1, FUS, UBQLN, OPTN, TREM2,
CHCHD10 and TBK1 genes have been described. Addi-
tional genes are expected to be found in near future. 
The purpose of this review is to describe recent ad-
vances in the molecular genetics of the FTLD spectrum
and to discuss implications for genetic counseling.
KEY WORDS: frontotemporal dementia, frontotemporal
lobar degeneration, C9orf72 gene, GRN gene, MAPT
gene.
Introduction
The term frontotemporal lobar degeneration (FTLD) was
coined to describe a pathology of the frontal and tempo-
ral lobes, commonly associated with cerebral deposition
of misfolded proteins (Lashley et al., 2015). FTLD de-
scribes a spectrum of clinically, pathologically and ge-
netically heterogeneous neurodegenerative disorders.
Three main clinical syndromes have been related to
FTLD, namely the behavioral variant of frontotemporal
dementia (bvFTD), the semantic variant (SD), and pro-
gressive non-fluent aphasia (PNFA). In addition, there is
a significant clinical, pathological and genetic overlap
with the atypical parkinsonian syndromes, like progres-
sive supranuclear palsy (PSP) and corticobasal syn-
drome (CBS), as well as amyotrophic lateral sclerosis
(FTD-ALS) (Bang et al., 2015).
In the early phase of the disease, bvFTD is clinically char-
acterized by progressive behavioral impairment and de-
cline in executive function associated with frontal lobe-
predominant atrophy, SD by a loss of object knowledge
with anomia and asymmetrical atrophy of the anterior
temporal lobes, and PNFA by expressive or motor speech
deficits with predominantly left peri-sylvian atrophy. With
the progression of the disease, a significant overlap be-
tween the different clinical syndromes may appear.
FTLD is a common cause of dementia in the general
population. Once thought to be rare, FTLD is now rec-
ognized to be at least as common as Alzheimer’s dis-
ease (AD) among middle-aged adults (Ratnavalli et al.,
2002). In the over-65s with dementia, the incidence of
FTLD ranks fourth, the top three being AD, Lewy body
dementia and vascular dementia. The medical, psycho-
logical, social  and economic costs of FTLD are enor-
mous (Scalmana et al., 2013). Despite the burden as-
sociated with the disease, at present there is no FDA-
approved therapy for it (Kerchner et al., 2011).
The neuropathology associated with FTLD is highly het-
erogeneous. From this perspective, the FTLD spectrum
can be split into two major categories: FTLD-tau, where
pathological inclusions contain fibrillar hyperphosphorylat-
ed tau, and  FTLD-TDP, characterized by neuronal and
glial inclusions immunoreactive for TDP-43. In addition,
there is a small group of tau-negative and TDP-negative
cases that are immunoreactive to components of the ubiq-
uitin proteasome system (FTLD-UPS) or the fused in sar-
coma protein (FTLD-FUS) (Josephs et al., 2011). In some
cases, however, molecular classification is still uncertain.
Among patients with FTLD, a variable percentage, be-
tween 20 and 40%, presents a positive familyhistory.
BvFTD shows the highest percentage of positive family
history, around 30-50% of patients, whereas in patients
with SD or PNFA the frequency is much lower. Howev-
er, only 10-30% of pedigrees shows a clear autosomal
dominant inheritance pattern of the phenotype (Le Ber,
2013). A recent study suggested that, even in patients
with late onset, FTLD is a genetic-based disease with
different inheritance modalities (Borroni et al., 2014).
The last two decades have seen tremendous advances
in appreciation of the clinical assessment, genetics and
molecular pathology of FTLD, thus offering hope for the
development of rational therapeutic strategies. The pur-
pose of this review is to describe recent advances in the
molecular genetics of the FTLD spectrum disorders and
to discuss the implications for genetic counseling.
Molecular genetics of FTLD
Recently, there has been an impressive evolution of ge-
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contributing to neurodegenerative disorders. Linkage
analysis, whole exome sequencing and genomewide
association studies (GWAS) have provided efficient ap-
proaches for detecting common and rare genetic varia-
tions contributing to FTLD risk. For the sake of clarity,
data regarding causative genes, mainly cloned in fami-
lies with autosomal dominant inheritance of the FTLD
phenotype, will be discussed first. We will then review
new genetic risk factors for the disease.
MAPT gene 
The MAPT gene, linked to chromosome 17, was the first
mutated gene identified, and it was discovered among
families who presented with frontotemporal dementia
(FTD) and parkinsonism (Hutton et al., 1998; Spillantini
et al., 1998). Specifically, this gene is located on chro-
mosome 17q21 and it consists of a non-coding exon fol-
lowed by 14 coding exons. MAPT encodes for micro-
tubule-associated protein tau protein (MAPT), whose
main function is stabilizing and promoting assembly of
microtubules (MTs), by binding to tubulin. MAPT plays al-
so a role in modulating vesicle and organelle transport
mediated by motor proteins along the MTs. Tau can be
found both in the peripheral and in the central nervous
system, where it is located mainly in neuron axons, as-
trocytes and oligodendrocytes. Alternative splicing
processes of exons 2, 3 and 10 of the MAPT gene give
rise to six main protein isoforms: three isoforms contain-
ing three amino-acid repeats (3R), and three isoforms
with four repeats (4R). More specifically, the exon 10
splicing decides the number of repetions (3R or 4R),
while the alternative splicing of exons 2 and 3 establish-
es the number of 29 amino acid  N-terminal insertions
(0N, 1N, 2N), which mediate tau interactions with plasma
membrane (Brandt et al., 1995). It has long been known
that tau protein undergoes a post-translation phosphory-
lation process in more than 25 sites and, notably, depo-
sition of hyperphosphorylated insoluble tau is a common
feature of several neurodegenerative disorders, collec-
tively known as tauopathies (AD, PSP, FTD, CBS, Nie-
mann-Pick disease) (Rademakers et al., 2004). 
At present, 72 different MAPT gene mutations and poly-
morphisms have been reported, including 44 that are
clearly pathogenetic (http://www.molgen.ua.ac.be), ac-
counting for 5-20% of familial FTLD cases (frequency of
mutations varies depending on the studied population,
ranging from 1% in Finland to 17.8% in the Nether-
lands). The mutations are mainly clustered from exon 9
to 13, encoding the four MT binding domains. Silent mu-
tations, missense mutations, in-frame single-codon
deletions and intronic mutations have also been found.
A substantial number of mutations are located in intron
10, leading to anomalous ratios of 3R to 4R tau
(D’Souza et al., 2000). The tubulin binding affinity of the
4R isoform is three times stronger than that of the 3R
isoform. The mutations thus disrupt the delicate equilib-
rium between cytoskeletal assembly and disassembly,
altering neuronal plasticity and axonal transport across
the MTs. Mutations of a second kind interfere with the
tau-tubulin interaction, reducing the capacity of tau to
stabilize and promote assembly of MTs, and thus pro-
moting an increased tendency of tau to form neurotoxic
aggregates. The hyperphosphorylation process also
has a negative role in the tau-MT interaction. The three
most common mutations account for about 50% of the
known mutations: the P301L mutation, associated main-
ly with bvFTD; the mutation involving the splice site in
exon 10 (IVS10+16 C>T); and the N279K mutation.
The neuropathological phenotype varies substantially in
morphological characteristics, severity and distribution,
depending on the type of MAPT gene mutation. Tau de-
posits may be abundant in the cerebral cortex, white
matter and some subcortical and brain stem nuclei.
Neurofibrillary tangles (NFTs) or Pick bodies in neurons,
as well as astrocytic plaques, tufted astrocytes, and
coiled bodies in oligodendroglial cells in the glial pathol-
ogy may be found. The location of the MAPT mutation
influences the type of cellular involvement (i.e. neurons,
astrocytes or oligodendroglia) and the type of neuronal
inclusion. Mutations in exons 1 and 10 (as well as in the
intron following exon 10) are associated with neuronal
and glial tau deposition, while mutations in exons 9, 11,
12 and 13 lead to deposits of tau filaments, mainly in
neurons. Mutations in exons 12 and 13 lead to the for-
mation of NFTs with paired helical and straight filaments
(indistinguishable from those seen in AD).
Since mutations in MAPT are typically associated with
neuronal and glial tau deposition, the clinical picture may
sometimes resemble other sporadic tauopathies such as
PSP and CBS. A significant variability in age at onset of
the disease (from 40 to 70 years) has been observed.   
Clinically, patients show the bvFTD phenotype, includ-
ing disinhibition and obsessive-compulsive behavior.
Extrapyramidal signs and symptoms may also be pres-
ent. Given the anterior medial temporal lobe atrophy
identified in patients carrying MAPT mutations, an SD-
like presentation associated with features of bvFTD can
also be observed. Although the clinical phenotype is
highly variable, early onset age, parkinsonism and ocu-
lomotor deficits should lead the clinician to suspect
MAPT mutation in the patient. However, the lack of a
clear correlation between MAPT gene mutations and
clinical features indicates that additional genetic and/or
environmental factors can produce significant phenotyp-
ic variations.
GRN gene
A major breakthrough occurred in 2006, when scientists
found that the progranulin (GRN) gene, a protein-coding
gene with 13 exons located on chromosome 17p21, was
responsible for another 5-20% of familial FTLD cases
and 1-5% of sporadic ones (Baker et al., 2006; Cruts et
al., 2006). GRN encodes progranulin, an ubiquitously
expressed growth factor precursor, which, together with
its products, is implicated in a wide range of biological
processes such as inflammation and wound repair, as
well as in pathological conditions including tumorigene-
sis (He et al., 2003; Ahmed et al., 2007). Progranulin is
predominantly expressed at the level of activated mi-
croglial cells and this finding seems to point to its regu-
latory role in the inflammatory response in the brain
(Philips et al., 2010). Although a neuroprotective role of
progranulin is universally recognized, the mechanism of
this function is still under investigation (Van Damme et
al., 2008; Tapia et al., 2011). Some experiments have
shown that, in stressed or GRN-depleted neuronal cells,
neurite outgrowth was obtainable by adding progranulin,
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pathways. Progranulin receptors are, at present, un-
known as well. Only sortilin-1 (SORT1), already known
as a receptor for other growth factors in brain, has been
demonstrated to bind, endocytose and regulate Pro-
granulin levels in vivo in human plasma. More recently,
a direct interaction with receptors for TNF-α has also
been reported. A role for progranulin in excitotoxicity
and synaptic transmission has also been suggested.
One the most dynamic aspects of the research on GRN
in recent years has been the study of factors, endoge-
nous and exogenous, able to regulate the gene expres-
sion. The role of microRNAs in regulating progranulin
expression is very intriguing and complex. In particular,
the minor T-allele of genetic variant rs5848, located in
the 3′ untranslated region of GRN, increases binding
with a specific microRNA, miR-659, to GRN, thereby re-
ducing progranulin levels (Rademakers et al., 2008).
Homozygous carriers of the T-allele of rs5848 have a
three-fold increased risk of developing FTLD-TDP com-
pared with homozygous C-allele carriers.
Worldwide, 149 different GRN gene mutations have
been described (http://www.molgen.ua.ac.be). Of these,
67 are clearly pathogenetic. Differently to MAPT, these
substitutions are scattered all over the gene. Generally,
GRN mutations are null mutations that lead to non-
sense-mediated decay of mutant GRN mRNA and re-
duced expression of progranulin. Consequently, muta-
tion carriers, even if asymptomatic, can be identified by
measuring plasma, serum and cerebrospinal fluid pro-
granulin concentrations (Finch et al., 2009). The most
frequently observed GRN mutations are the R493X non-
sense mutation in exon 11, and the c.-8+5 G>C (IVS0+5
G>C) substitution in a splicing site in intron 0.
Recent studies have shown, in FTLD patients carrying
the GRN gene mutation, that the ubiquitinated neuronal
inclusions contain, as a major component, the TAR DNA
binding protein (TDP-43). A loss of function of progran-
ulin leads to defective ubiquitination, resulting in accu-
mulation of TDP-43.
Mutation penetrance is very high, with 90% of carriers
manifesting symptoms by the age of 75, and the associ-
ated phenotypes are remarkably variable, both between
families with different GRN mutations and among mem-
bers of a single family. The mean age at onset is around
60 years and the mean duration of disease is about 8
years (range 3-22 years). Social withdrawal and apathy
are the most common behavioral changes. About 1/3 of
patients, at presentation, shows early isolated language
dysfunction, suggestive of a non-fluent type. Hallucina-
tions and delusions are frequently concomitant. Episod-
ic memory deficits may also occur, leading to a clinical
diagnosis of the amnestic variant of mild cognitive im-
pairment or, if they occur together with parietal deficits,
like dyscalculia, visuospatial dysfunction, and limb
apraxia, to an erroneous diagnosis of AD. Extrapyrami-
dal signs are frequently observed and include CBS with
asymmetric parkinsonism, dystonia and limb apraxia.
Amyotrophic lateral sclerosis (ALS) is only a very rare
part of the clinical spectrum within GRN families.
C9orf72 gene 
The past decade has seen an accumulation of strong
evidence suggesting that the presence of a locus on
chromosome 9p21 is of pivotal importance in a com-
bined FTLD-ALS phenotype. Familial clusters of FTLD
and/or ALS phenotypes with autosomal dominant trans-
mission were found to have, in common, a region of 3.7
MB containing only ten known genes. In 2011, through
PCR and Southern blot analysis techniques, it was fi-
nally discovered that the disease was related to a hexa-
nucleotide (GGGGCC) repeat located in a non-coding
region of the C9orf72 gene. This result was reached si-
multaneously by two independent studies, one on an
FTD-ALS family designated as VSM-20 (Vancouver,
San Francisco and Mayo family), the other on a Welsh
family (DeJesus et al., 2011; Renton et al., 2011).
The C9orf72 gene consists of 12 exons encoding for
three different transcripts and two protein isoforms,
called a and b, whose function and distribution in the
structures of the brain are still under investigation. Iso-
form a, the longest one (481 amino acids), originates
from transcripts 1 and 3, while transcript 2 codes for the
shorter isoform b (222 amino acids). Inside the cell, they
can be found within the neuronal cytoplasm and in the
presynaptic terminals. Although the function of the
C9orf72 protein is currently unclear, recent studies clas-
sify it as homologous to the DENN (differentially ex-
pressed in normal and neoplastic cells) class of pro-
teins, which are characterized by a conserved DENN
module consisting of an N-terminal longin domain, fol-
lowed by the central DENN and the C-terminal alpha-
helical d-DENN domains. This class of proteins works
as GDP/GTP exchange factors for small GTPases of the
Rab family, with a role in vesicular trafficking regulation
and neuronal autophagy. In healthy subjects, the num-
ber of GGGGCC (G4C2) repeats is less than 10, al-
though 30 is universally accepted as a non-pathological
limit. By contrast, in expanded individuals, the number
of repeats ranges from a minimum of 400 to several
thousand.    
Several studies have demonstrated that C9orf72 patho-
logical expansion is a major cause of both familial FTLD
(12%) and ALS (22.5%), with a higher prevalence in
northern Europe and, more specifically, in genetically
isolated populations, for example in Sardinia and Fin-
land. In the Finnish population, in particular, the C9orf72
mutation reaches a prevalence of 46% of all familial
ALS, 21.1% of sporadic ALS, and 29.3% of familial
FTLD subjects. Another study, performed in a Flanders-
Belgian cohort of FTLD, ALS and FTLD-ALS subjects,
showed that, in FTLD cases, C9orf72 expansion occurs
at a frequency comparable with that of mutations in
GRN (6 vs 7%). Although most of the patients included
in screening studies are Caucasian, C9orf72 expan-
sions have also been identified in Middle Eastern,
African-American and Asian patients. It is interesting to
note that, regardless of clinical presentation or ethnic
origin, all the patients carrying the C9orf72 variant in-
herit the expansion on the same genetic background,
suggesting the presence of a founder effect or, alterna-
tively, the presence of multiple independent expansions
of a fragile haplotype that predisposes to disease. Re-
cently, the first experimental evidence has emerged on
the role of C9orf72 in the regulation of endosomal traf-
ficking and neuronal autophagy. The expansion is locat-
ed between two non-coding exons, 1a and 1b, and cur-
rently there are three main hypotheses about its influ-
ence on transcriptional products and the consequent
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C9orf72 isoform leads to haploinsufficiency, resulting in
exocytic/endocytic membrane trafficking dysfunction.
The expanded hexanucleotide resides in the core region
of the promoter of transcript 1, whose reduction by at
least 50% has been demonstrated in several studies.
However, since in transcripts 2 and 3 the expansion is
incorporated in intron 1 and produces an aberrant tran-
script, the second hypothesis suggests a gain-of-func-
tion mechanism. The accumulation of repeats contain-
ing GGGGCC transcripts as nuclear RNA aggregates
(“foci”) found in the frontal cortex and spinal cord of car-
riers of mutated C9orf72 suggested RNA toxicity as a
third hypothesis. Similarly to what happens in other dis-
orders, these RNA aggregates may produce alterations
in gene expression and/or alternative splicing of tran-
scripts, or disrupt the functionality of one or more RNA
binding proteins. Recently, Mori et al. (2013)  demon-
strated that the intronic G4C2 repeats might be aber-
rantly translated into dipeptides, poly-(Gly-Ala) and, to a
lesser extent, poly-(Gly-Pro) and poly-(Gly-Arg) dipepti-
de-repeat proteins. It is also possible that all the afore-
mentioned mechanisms, to variable extents, contribute
to different clinical phenotypes.
The neuropathology associated with the C9orf72 muta-
tion is a combination of FTLD-TDP and ALS (Hsiung et
al., 2012). Post-mortem examination usually shows
TDP-43-positive inclusions in the basal ganglia, sub-
stantia nigra, hippocampus, extramotor cerebral cortex
and lower motor neurons of the brainstem and spinal
cord. Nevertheless, the majority of reports agrees that
there is a specific pattern of neuropathological charac-
teristics with p62-positive, TDP-43-negative inclusions.
These characteristic neuronal inclusions can be found in
several neuroanatomical sites, but the hippocampal py-
ramidal neurons and cerebellar granule cell layer seem
to be the most affected (Al-Sarraj et al., 2011).
Clinically, the predominant phenotype in these patients
is bvFTD associated with ALS, although the presenta-
tion may vary widely even within the same family
(bvFTD or ALS or a combination of both diseases) (Mur-
ray et al., 2011; Van Langenhove et al., 2013). Consid-
ering the FTLD spectrum, the most represented subtype
is bvFTD, whereas PNFA is the least frequent. Psy-
chosis and obsessive compulsive disorders are com-
mon at the onset of the disease (Arighi et al., 2012; Gal-
imberti et al., 2013). Memory deficits at presentation are
very frequent (in up to 50-65% of cases), presenting the
clinician with a challenging differential diagnosis with
AD. On examination, cerebellar and extrapyramidal
signs may also be present. A case showing mystical
delirium, visual and auditory hallucinations at onset, in
the absence of neurological symptoms and brain atro-
phy, has also been reported. Age at onset age ranges
from 27 to 83 years, with an average of 50 years. The
duration of the disease can vary, ranging from 1 to 22
years. Neuroimaging shows symmetrical frontal and/or
temporal lobe atrophy, but parietal, occipital and cere-
bellar atrophy can also appear.
CHMP2B gene
In 2005, using a linkage analysis approach, FTLD was
linked to chromosome 3 in a Danish family (FTD-3).
Subsequently, a mutation was identified in the chro-
matin-modifying protein 2B (CHMP2B) gene on chromo-
some 3p11.2 (Van der Zee et al., 2008). This gene en-
codes a component of the highly conserved ESCRT-III
(endosomal sorting complex required for transport III)
heteromeric complex, which plays a role in the recycling
or degradation of cell surface receptors, in endosomal
lysosomal and autophagic degradation pathways, and
spine growth. CHMP2B has six exons and is expressed
in neurons of all major brain regions. The first identified
mutation occurs in the splice acceptor site for the final
CHMP2B exon, leading to the formation of two novel
transcripts termed CHMP2BIntron5 and CHMP2BDel-
ta10
, which replace the final 36 amino acids with either
a single valine residue (CHMP2BIntron5) or a 29-amino-
acid nonsense sequence (CHMP2BDelta10). In 2008, a
missense mutation (CHMP2BQ165X) was identified in
an FTLD family. Both mutations (accounting for less
than 1% of the FTLD population) affect the C-terminus
of the protein, leading to its deletion.
Histological observation shows enlarged vacuoles in the
frontal cortex and parietal, temporal and occipital neu-
rons, probably due to altered endosome lysosome fu-
sion and autophagic mechanism impairment (Urwin et
al., 2010). Cytoplasmic inclusions are negative for tau,
TDP-43 and FUS, consistent with the pathological clas-
sification of FTLD-UPS. Clinically, early behavioral
changes are a common onset symptom, suggesting a
bvFTD, but a minority of patients have been reported to
show a particular progressive aphasia characterized by
a spontaneous reduction of speech, which hesitates
sometimes in silence, and preserved reading and repe-
tition skills. This picture cannot be linked to a specific di-
agnosis of PNFA, or SD, but is more suggestive of  “dy-
namic aphasia”. Later in the disease course, parkinson-
ism, dystonia, pyramidal signs and myoclonus can be
observed. The age at onset is between 46 and 65 years,
with an average of 58 years.
VCP gene
Mutations in valosin-containing protein (VCP), a 17-ex-
on protein-coding gene located on chromosome 9p13.3,
were identified in 2004 through a linkage analysis in
families presenting IBMPFD,  a complex clinical picture
characterized by muscle weakness due to inclusion
body myopathy (IBM), osteolytic lesions compatible with
Paget’s disease of bone (PDB), and autosomal domi-
nant FTLD (Watts et al., 2004).  Recently, VCP muta-
tions have also been found in Charcot-Marie-Tooth dis-
ease type 2, in ALS and in schizophrenia. The VCP pro-
tein is a member of a family that includes putative ATP-
binding proteins involved in vesicle transport and fusion,
and in proteasome function. It also plays a role in den-
dritic spinogenesis and in several cellular events related
to mitosis (including homotypic membrane fusion, and
spindle pole body function) and ubiquitin-dependent
protein degradation. 
Today there are 18 known mutations in this gene, iden-
tified in 41 independent families, and the R155H muta-
tion, found in exon 5, is the most frequent. The pene-
trance is incomplete for the three typical clinical condi-
tions and patients may present only one clinical pheno-
type. All IBMPFD mutations are found in the interface
site of the ATPase D1 and the N-domain of the CDC48-
like protein and affect protein degradation and/or pro-












system. However, mutations in VCP are rare and ac-
count for less than 1% of cases of familial FTLD.
Pathologically, FTLD patients carrying VCP mutations
show several cytoplasmic and nuclear intraneuronal in-
clusions and dystrophic neurites, consistent with a TDP-
43 proteinopathy (Snowden et al., 2012). Symptoms oc-
cur in the sixth decade of life in 25-30% of IBMPFD pa-
tients and penetrance of the three clinical conditions
(IBM, PDB, FTLD) is independent of the underlying mu-
tation. BvFTD and SD are the FLTD subtypes most fre-
quently reported.
TARDBP gene
The identification of TDP-43-derived protein species as
the major constituent of the aggregates found in patients
with FILD related to ubiquitin deposition (FTLD-U) led to
the identification of transactive response DNA-binding
protein (TARDBP) gene mutations (Arai et al., 2006).
The TARDBP gene is constituted by six transcribed ex-
ons and located on 1p36.22. The protein it encodes is
TDP-43, whose major form is translated from exons 2-6,
resulting in a 414-amino-acid polypeptide, a highly con-
served protein, predominately nuclear localized, able to
move between nucleus and cytoplasm. It forms hetero-
geneous nuclear ribonucleoprotein (hnRNP)  complexes
with numerous functions related to RNA regulation, such
as the control of splicing, mRNA stability and transport,
and others yet to be investigated. It acts as a transcrip-
tional repressor that binds to chromosomally integrated
TAR DNA and represses HIV-1 transcription. Recently,
in animal models, TDP-43 has been shown to regulate
axon growth in vitro and in vivo, a finding suggesting
that the capacity of spinal motor neurons to produce and
maintain an axon is compromised by TDP-43 dysregu-
lation and that disruption of cytoskeletal integrity may
play a role in the pathogenesis of both ALS and FTLD
(Polymenidou et al., 2011).
Mutations in TARDBP have been linked to both ALS and
FTLD-TDP, suggesting that TDP-43 dysfunction is
mechanistic in causing disease, but while 5% of familial
ALS patients have a TARDBP mutation, these are rarely
found in FTLD and FTD associated with motor neuron
disease (FTD-MND). The current list of TARDBP gene
mutations includes over 40 different missenses, most of
them residing in the C-terminal glycine-rich domain, en-
coded by exon 6 and involved in protein-protein interac-
tions. Since TDP-43 is a constituent part of hnRNP, it is
reasonable to hypothesize that impaired common hn-
RNP functions could affect certain pathways leading to
neuron dysfunction and degeneration. More than 6000
RNAs are known to interact with TDP-43 but, to date,
few of them have been studied as possible disease-rel-
evant targets. Nevertheless, it remains unclear whether
the main disease mechanism involved in TDP-43-asso-
ciated cell death is a loss-of-function or a gain-of-func-
tion one (or both). In fact, while the identification of
TARDBP mutations provides evidence that TDP-43 dys-
function is linked to neurodegeneration, their functional
consequences are still under investigation. Current in vi-
vo models show that both increased and reduced ex-
pression levels of TDP-43 can be noxious for cells, but
no model has been able to fully reproduce the neu-
ropathological and biochemical features of human TDP-
43-related diseases.
The pathological form of TDP-43 accumulating in neu-
ronal and glial inclusions in FTLD and ALS consists of
abnormally ubiquitinated and hyperphosphorylated C-
terminal fragments, after a redistribution of TDP-43 itself
from the nucleus to the cell cytoplasm. Although, in the
literature, TARDBP mutations have been appreciated as
a cause of ALS phenotypes more than pure FTLD ones,
they can give rise to the full ALS-FTLD continuum, even
to early-onset pure FTLD with no evidence of ALS even
in advanced FTD disease stages. Hence, TARDBP
screening might be considered in young patients with
pure neuropsychiatric symptoms and no neurodegener-
ative disease history in their pedigree.
SQSTM1 gene
Mutations in the sequestosome 1 (SQSTM1) gene were
initially identified as a cause of PDB, a common disorder
of bone metabolism characterized by increased tissue
turnover. More recently, mutations in SQSTM1 have
been found in both sporadic and familial ALS patients
(Fecto et al., 2011). Finally, in 2012, SQSTM1 gene mu-
tations were also found in FTLD patients (Rubino et al.,
2012). SQSTM1 is an 11-exon gene located on 5q35
and it encodes p62, a  440-amino-acid adapter protein
containing several protein-protein interaction domains
with multiple functions in signal transduction regulating
osteoclast differentiation, activity and survival. P62 also
acts as a transport factor that directs ubiquitinated pro-
teins to the autophagic degradation or proteasome path-
way, playing a key role in the formation of ubiquitin-pos-
itive protein inclusions in neurons with defective au-
tophagy. The protein also has an important function as a
scaffolding/adaptor protein in concert with TNF receptor-
associated factor 6, mediating activation of NF-kB in re-
sponse to upstream signals. There is growing evidence
implicating p62 in neurodegeneration: SQSTM1 knock-
out mice develop memory deficits associated with accu-
mulation of hyperphosphorylated tau and NFTs (Ra -
mesh Babu et al., 2008). In addition, pathological stud-
ies in humans have demonstrated increased immunore-
activity for p62 in several neurodegenerative diseases
such as AD disease, Lewy body dementia, FTLD, Par -
kinson’s disease and Huntington’s disease (Zatloukal et
al., 2002; Geetha et al., 2012). Aggregation of TDP-43,
the main protein accumulating in neuronal cells of both
FTLD and ALS patients, can be significantly reduced by
overexpression of p62. Detailed histopathology demon-
strated that mutations in SQSTM1 are related to wide-
spread neuronal and glial phospho-TDP-43 pathology.
Autoptic investigations have shown that FTLD or ALS
carriers of C9ORF72 expansions have a larger number
of p62-positive inclusions. According to a recent de-
scription of a new role of p62 in maintaining mitochon-
drial integrity, a portion of p62 localizes directly within
the mitochondria and stabilizes the electron transport by
forming heterogeneous protein complexes (Lee and
Shin, 2011). P62 interacts with several oxidizable pro-
teins, including some components of the electron trans-
port chain, and with chaperones and redox regulatory
enzymes.
SQSTM1 gene mutations in FTLD patients have been
confirmed by several studies. However, at present, no
clear genotype-phenotype correlations have been
demonstrated. It seems appropriate to check for bone
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metabolism alterations in patients who present signs
and symptoms of FTLD or ALS, whereas patients with
PDB should be carefully evaluated for signs of demen-
tia and motor neuron disease.
FUS gene
Fused in sarcoma (FUS) is a highly conserved, ubiqui-
tously expressed protein-coding gene located on
16p11.2. The gene encodes for the FUS protein, a 526-
amino-acid protein component of the hnRNP complex
and a member of the FET protein family, which also in-
cludes Ewing’s sarcoma protein (EWS) and TATA-bind-
ing protein-associated factor 15 (TAF15). These are pre-
dominantly nuclear multifunctional DNA/RNA binding
proteins (like TDP-43), implicated in cellular processes
that include regulation of gene expression, maintenance
of genomic integrity and mRNA/microRNA processing.
FUS protein has an amino-terminal region rich in QGSY
residues, a glycine-rich region, an RNA recognition mo-
tif, two RGG domains, and a zinc finger motif. Of utmost
importance is the prion-like domain of FUS, residing in
the amino-terminal region, which plays a critical role in
FUS misfolding. 
Purified FUS is, in fact, extremely prone to aggregation
and it aggregates more rapidly than TDP-43.  
In 2009, FUS mutations were discovered to be the
cause of about 3% of familial ALS cases (Kwiatkowski et
al.), and shortly afterwards inclusions composed of FUS
were shown to account for the bulk of remaining
tau/TDP-negative FTLD cases, which include atypical
FTLD-U, basophilic inclusion body disease and neu-
ronal intermediate filament inclusion disease. In most
cell types, FUS is present in both the nucleus and the
cytoplasm, but in neurons there is proportionally more in
the nucleus, with smaller amounts in the cytoplasm, and
the expression in the glia can even be exclusively nu-
clear (Mackenzie et al., 2010). In FTLD, the ability of
FUS to shuttle to the nucleus is impaired because of an
unspecified transportin-mediated nuclear import defect;
this results in cytoplasmic accumulation of the full-length
protein in stress granules. Interestingly, staining for
TDP-43 and FUS appears to be mutually exclusive, sug-
gesting that they are distinct subtypes of FTLD-U. It is
also noteworthy that in all FTLD-FUS subtypes TAF15,
and EWS co-accumulate in FUS-positive inclusions,
and a reduction in the normal nuclear staining of all
three FET proteins, particularly TAF15 was also found in
inclusion-bearing cells, suggesting a hypothetical in-
volvement of all FET proteins in neurodegeneration
(Neumann et al., 2011). 
Disease-causing mutations, mostly located in the car-
boxy-terminus of the protein, seem to cause protein cy-
toplasmic mislocalization. This could happen through
two different mechanisms: a defect in transportin, re-
ducing the efficiency of nuclear import of all FET pro-
teins, or certain unknown posttranslational modifications
of FET proteins, decreasing their solubility. Similar to
TDP-43, both a loss of functions and a gain of toxic
properties via their sequestration in aggregates are
plausible.
FTD-FUS should be suspected in patients with onset of
symptoms before 40 years of age, with no family history
of FTLD, and with atrophy of the frontoinsular and cin-
gulate cortex and of the head of the caudate nucleus on
the neuroimaging study (Josephs et al., 2010). The ex-
istence of cases of primary progressive aphasia (PPA)
with FUS inclusions remains to be demonstrated.
UBQLN2 gene
Ubuiquilin 2 (UBQLN2) is an intronless gene on
Xp11.21, discovered in 2011 as a cause of X-linked ALS
and ALS/dementia (Deng et al., 2011). Ubiquilin 2 pro-
tein is a member of the ubiquilin family of proteins which
are characterized by the presence of an N-terminal
ubiquitin-like domain and a C-terminal ubiquitin-associ-
ated domain. These proteins physically associate with
both proteasomes and ubiquitin ligases and they are
thought to functionally link the ubiquitination machinery
to the proteasome to mediate ubiquitinated protein
degradation.
UBQLN2 mutations are rare in Central European ALS
and FTLD patients, but they seem to be more frequent
in the sporadic disease forms. Mutated UBQLN2 can
give rise to the full ALS-FTLD continuum. Immunohisto-
chemistry studies reported that mutated ubiquilin 2 ac-
cumulates in neuronal inclusions in the brain and spinal
cord. Importantly, a correlation of hippocampal UBQLN2
pathology with dementia in ALS cases with or without
UBQLN2 mutations has been found, suggesting that the
UBQLN2 gene could be involved in ALS-related demen-
tia, even without UBQLN2 mutations. In addition,
ubiquilin 2 pathology has been  found in association with
inclusion bodies in synucleinopathies and polyglutamine
diseases, leading to the hypothesis that it may be a
common downstream mechanism in neurodegenerative
diseases.
OPTN gene
In 2010, homozygous deletions of exon 5 of the gene
encoding optineurin (OPTN) were described in Japan-
ese siblings affected by ALS (Maruyama et al., 2010).
OPTN is a 16-exon gene located on 10p13, encoding for
the coiled-coil containing protein optineurin. 
This gene may play a role in normal-tension glaucoma
and adult-onset primary open angle glaucoma, and may
also be involved in cellular morphogenesis, membrane
and vesicle trafficking, and transcription activation
through its interactions with the RAB8, huntingtin and
transcription factor IIIA proteins. Like other proteins al-
ready described, optineurin also seems to be involved in
protein degradation via autophagy. 
The pathomechanism causing the disease may be dif-
ferent depending on the recessive and dominant nature
of the underlying mutation. For example, it is thought
that ALS due to a recessive mutation might show a loss
of function resulting from nonsense-mediated mRNA de-
cay of transcription; in any case, it is very difficult to con-
firm any hypothesis because the lack of autopsy materi-
al in these recessive families precludes extensive
histopathological analyses. Intriguingly, OPTN has also
been linked to PDB. OPTN is co-localized with TDP-43
in the characteristic inclusion bodies of sporadic ALS.
More generally, TDP-43, FUS and OPTN are compo-
nents of pathological inclusions seen in SOD1-negative
familial ALS, sporadic ALS, and ALS-FTLD, but not in
SOD1-linked ALS. 













The triggering receptor expressed on myeloid cells 2
gene (TREM2) is a 5-exon encoding gene on 6p21.1
whose product is a membrane protein that forms a re-
ceptor signaling complex with the TYRO protein tyrosine
kinase binding protein. 
This protein is a member of the innate immune receptor
TREM family, expressed on the cell surface of the
monocyte-macrophage lineage including monocyte-de-
rived dendritic cells, osteoclasts and microglia in the
central nervous system. TREM2 plays a role in the im-
mune response and may be involved in chronic inflam-
mation by triggering the production of constitutive in-
flammatory cytokines. Defects in this gene are a cause
of a genetic syndrome named Nasu-Hakola disease
(NHD), also known as polycystic lipomembranous os-
teodysplasia with sclerosing leukoencephalopathy,
which is characterized by early-onset progressive de-
mentia associated with sclerosing leukoencephalopathy
and systemic bone cysts (Madry et al., 2007). The early
onset of dementia as well as the marked involvement of
the frontal regions in NHD are features resembling
FTLD. In January 2013, a study identified different ho-
mozygous mutations in TREM2 in three Turkish
probands among 44 identified with FTLD spectrum-like
disease (Guerreiro et al., 2013). None of these three pa-
tients had a typical clinical presentation of NHD: they
presented with behavioral changes and subsequent
cognitive impairment and motor features, but without
any bone cysts or bone-associated phenotypes.
To date, 14 different mutations have been identified in
TREM2. Recently, an increased frequency of rare het-
erozygous TREM2 variations was also detected in AD
patients (Jonsson et al., 2013). 
One rare variant, p.R47H (rs75932628), showed a
strong association with late-onset AD, comparable to the
association with the APOE ε4 allele (although it occurs
with a much lower frequency). The p.R47H variant is lo-
cated in TREM2 exon 2, where several homozygous
FTLD mutations were also observed. This exone en-
codes both the signal peptide and part of the extracellu-
lar domain containing an IgV-set domain: hypothetically,
TREM2 mutations might contribute to the neurodegen-
erative process leading to an altered immune response
with extensive inflammation or defective microglial func-
tion or survival. Since the association of the gene with
FLTD, mutations in TREM2 have been shown to be as-
sociated with atypical signs in examined patients:
epilepsy, parkinsonism, early parietal and hippocampus
involvement, and corpus callosum thickness on brain
MRI. This gene should be taken into account when mu-
tations in other dementia genes are excluded.
CHCHD10 and TBK1 genes
Very recently, two new genes have been reported to be
mutated in patients with FTLD: CHCHD10 (coiled-coil-
helix-coiled-coil-helix domain containing 10) is located
on chromosome 22 and encodes a mitochondrial protein
that is enriched at cristae junctions in the intermem-
brane space, while the TBK1 (TANK1-binding kinase 1)
gene, located on chromosome 12, encodes a serine/
threonine kinase that plays an essential role in regulat-
ing inflammatory responses to foreign agents. Rarely,
mutations in these genes have been associated with
both FTLD and ALS (Zhang et al., 2015; Freischmidt et
al., 2015).
Table I lists all the genes at present involved in FTLD
etiopathogenesis, together with their chromosomal lo-
calizations, frequencies and suggested mechanisms of
action. 
Genetic risk factors
In addition to the above-mentioned genes, generally
cloned in families showing autosomal dominant trans-
mission of the FTLD spectrum, several genetic factors
that are probably involved in the disease as modifier
genes have also been studied. The first candidate gene
studied in FTLD was the APOE gene, a well-known risk
factor for AD. Preliminary case-control studies reported
conflicting results: some Authors found a significant as-
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Table I - Frequency of gene mutations and disease mechanisms in frontotemporal lobar degeneration.
Gene Location Gene product Frequency in Disease mechanism
familial cases %
MAPT 17q21 Tau 7.1 – 10.5 Toxic protein
GRN 17p21 Progranulin 6.5 – 31.5 Autophagy/lysosomal pathway/inflammation
C9orf72 9p21 C9orf72 protein 12.0 – 34.5 Endosomal trafficking/toxic RNA/immune regulation
CHMP2B 3p11.2 Chromatin-modifying protein 2B Rare Autophagy/lysosomal pathway
VCP 9p13.3 Valosin-containing protein Rare Autophagy
TARDBP 1p36.22 TDP-43 Rare DNA/RNA
SQSTM1 5q35 P62 2.0 - 3.2 Autophagy
FUS 16p11.2 Fused in sarcoma Rare DNA/RNA
UBQLN2 Xp11.21 Ubiquilin 2 Rare Autophagy
OPTN 10p13 Optineurin Rare Autophagy
CHCHD10 22q11.23 Coiled-coil-helix-coiled-coil-helix Rare Mitochondrial function
domain containing 10
TBK1 TANK-binding kinase 1 1.7 – 4.5 Autophagy
TREM2 6p21.1 Triggering receptor expressed Rare Inflammation












sociation between the ε4 allele of the APOE gene and
the disease risk while others were not able to confirm
this association. 
A recent meta-analysis showed that carriage of the ε4
allele was associated with a two-fold increased disease
risk (Rubino et al., 2013). In 2010, multiple single-nu-
cleotide polymorphisms (SNPs) mapping to a single
linkage disequilibrium block on 7p21 that contains trans-
membrane protein 106B (TMEM106B) were identified
as genetic risk factors for FTLD associated with TAR
DNA-binding protein 43 kDa-positive inclusions (FTLD-
TDP) (Giraldo et al., 2013). Multiple replication studies
have been conducted in FTLD populations of different
geographical origins, confirming this association.
Recently, evaluation of a role for GRN in sporadic FTLD
has provided evidence that a single SNP in the GRN
promoter may influence the disease risk (Galimberti et
al., 2010). In addition, nitric oxide synthase (NOS)3
G894T and NOS1 C276T SNPs likely increase the risk
of developing FTLD. Further genetic risk factors, include
BCL2-associated athanogene 1 (BAG1), Kinesis family
member 24 (KIF24), and defective in cullin neddylation
1 (DCN-1)-domain containing 1 (DCUN1D1) (Villa et al.,
2009; Venturelli et al., 2010).
The first GWAS on FTLD patients was performed by
Van Deerlin et al. (2010). A group of 515 individuals af-
fected by FTLD with autopsy-proven TDP-43 inclusion
pathology (FTLD-TDP) was compared with 2509
healthy controls and an association with three SNPs
mapping to a single linkage disequilibrium block on
7p21 was shown. This region contains the already de-
scribed TMEM106B gene. These findings, however,
were not confirmed by replication studies performed in
two clinical FTLD cohorts of British origin.
More recently, a two-stage GWAS study was performed
in a large cohort of 3526 FTLD patients in comparison
with 9402 healthy controls. A significant association at
6p21.3, HLA locus, together with a potential novel locus
at 11q14, encompassing RAB38/CTSC (the transcripts
of which are related to lysosomal pathway), was found
for  bvFTD (Ferrari et al., 2014). These findings suggest
that immune system processes and possibly lysosomal
and autophagy pathways are potentially involved in
FTLD.
Genetic counseling
The identification of an increasing number of genes in-
volved in FTLD is moving the field of genetic counseling
in a new and challenging direction. In the majority of the
FTLD patients, the clinical phenotype is related to ge-
netically complex mechanisms, wherein many genetic
variations of small effect interact to increase the risk of
dementia. 
A small proportion of families have an autosomal domi-
nant family history of FTLD, caused by a mutation in one
of the aforementioned genes. In approaching genetic
counseling, the neurologist should obtain a detailed
three-generation pedigree that captures the presence of
FTLD, ALS, other dementias, parkinsonism, and also
psychiatric conditions. 
The pedigree should also include ages at disease onset,
diagnoses and ages at death. 
Medical records, including autopsy studies if available,
are essential to clarify diagnoses. In patients with auto-
somal dominant transmission of the disease, genetic
counseling should include a discussion of the 50% risk
to offspring of an expansion carrier, regardless of
whether or not this expansion is de novo. In the remain-
ing families, the characteristics of a genetically complex
disease should be carefully explained. For the individual
who is cognitively or behaviorally impaired, genetic
counseling should involve a healthcare proxy, legal
guardian or next of kin. Genetic counseling should take
into account the uncertainties about the pathogenicity
and the penetrance of some genetic mutations, the pos-
sible presence of mutations of different genes in the
same individual, and the poor genotypic/phenotypic cor-
relation in most FTLD genes.
Concluding remarks
In the last decade, several genes have been cloned in
families segregating the FTLD phenotype as an autoso-
mal dominant trait. Genetic variants in the MAPT, PGRN
and C9orf72 genes are present in approximately 40% of
familial FTLD cases. Mutations in several additional
genes (CHMP2B, VCP, TARDBP, SQSTM1, FUS,
UBQLN, OPTN, TREM2, CHCHD10 and TBK1), even if
present with a low frequency, are of particular interest in
order to elucidate the complex pathophysiological
mechanisms of the disease. In addition, several genetic
risk factors for FTLD have been reported. Taken togeth-
er, these recent genetic findings highlight the genetic
heterogeneity of the disease and suggest new thera-
peutic strategies.
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